Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218023 · ClinicalTrials.gov registry record · Phase 2
Medications for Stopping Cocaine Dependence and Preventing Relapse
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00218023 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 101 participants.
The verdict
NCT00218023, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to identify subpopulations and baseline conditions that are most responsive to treatment for cocaine dependent individuals.
Interventions
- DRUG Placebo
- DRUG Modafinil
- BEHAVIORAL Motivational Interviewing (MI)
- DRUG Levodopa/Carbidopa
- DRUG Naltrexone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218023
The ClinicalTrials.gov registry entry for NCT00218023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00218023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218023 about?
NCT00218023 is a clinical study titled "Medications for Stopping Cocaine Dependence and Preventing Relapse". Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to identify subpopulations and baseline conditions that are most responsive to treatment for cocaine dependent individuals.
What is the current status of trial NCT00218023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2006-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00218023?
The interventions under investigation include: Placebo (DRUG), Modafinil (DRUG), Motivational Interviewing (MI) (BEHAVIORAL), Levodopa/Carbidopa (DRUG), Naltrexone HCl (DRUG).
Who is sponsoring clinical trial NCT00218023?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.